

Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

<https://marketpublishers.com/r/GF9A3D8EE43EN.html>

Date: March 2018

Pages: 300

Price: US\$ 2,400.00 (Single User License)

ID: GF9A3D8EE43EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price & Clinical Pipeline Outlook 2024” Report Highlights:

Global TNF Inhibitors Market Trends

Key TNF Inhibitors Drug Sales, Price & Dosage Analysis

Global TNF Inhibitors Clinical Pipeline by Company, Indication & Phase

Sales Projections of Key Drugs Till 2024

Clinical Pipeline Data by Phase

TNF Inhibitors Market Future Outlook

Marketed Drug Clinical & Patent Insight

Tumor Necrosis Factor (TNF) is a vital protein that plays a key role in the regulation of immune cells. Several Clinical studies have proved that the level of TNF is significantly high in patients suffering from Autoimmune Diseases like Rheumatoid arthritis, Ankylosing Spondylitis and Crohn's Disease. Each of these indications have shown high prevalence globally in the past few years with million of new incidence being reported every year.

This discovery has lead pharmaceutical companies to develop therapeutics which aims at inhibiting the overexpression of TNF. TNF inhibitors, also known as Anti TNF therapeutics work by attaching to TNF receptors, thus lowering the levels of TNF in the body; resulting in prevention of inflammatory response and chronic pain. The use of TNF inhibitors in each of the above mentioned clinical conditions have been found to provide excellent therapeutic efficacy with minimal side effects, thus making them global leaders in the autoimmune disorder, pain management and inflammatory therapeutic segment.

Etanercept (Enbrel), Infliximab (Remicade), Adalimumab(Humira) , Certolizumab, and Golimumab(Simponi) are the key therapeutics that make up the global TNF inhibitors Market. Among these, Humira and Remicade have made it to the list of Blockbuster drugs of 2017 with global sales of US\$ 17.6 Billion and US\$ 5.9 Billion Respectively. Remicade is closely followed by another TNF inhibitor Enbrel, with global sales of US\$ 5.8 Billion.

With the launch of biosimilar version of each TNF inhibitors, the global TNF inhibitors market is bound to undergo a dynamic change with respect to revenues.

Factors like patent expiration, involvement of emerging biotechnology and pharmaceutical firms, collaboration and support from regulatory authorities for easy approval has facilitated the commercialization of novel TNF inhibitors and their biosimilars.

Although the TNF inhibitors market is being flooded with wide range of TNF Biosimilars; certain therapeutics are bound to remain dominant in the global TNF inhibitors market. For instance, Despite Humira being one of the earliest therapeutic in the market, it has managed to acquire the largest market size globally. The success of Humira indicates high market potential in the newly approved therapeutics that are anticipated to enter the market soon, thus proving that the TNF inhibitor segment is here to stay.

While North America is still the Dominant market when it comes to TNF inhibitors; Analysis shows the market dominance shifting towards European and Asian regions during the forecast period. Patent Expiry of Existing TNF inhibitors, Favorable reimbursement plans, lenient drug regulation laws are few key reasons for the shift of the TNF inhibitors market towards the European and Asia Pacific Region. Further, launching of new products, advancement in scientific and technical aspect of Drug development and increasing investment in healthcare are fuelling factors that provide an

optimistic forecast in the developing Asian regions like China and India.

Global Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are key factors that drive the TNF inhibitors market. Studies indicate that 20% of the global population is suffering from some kind of chronic pain, with rheumatoid arthritis showing the highest prevalence. Estimated data indicates that the number of people suffering from Rheumatoid arthritis alone might rise to over 78 Million by 2040, thus ensuring exponential growth to the TNF inhibitors Market.

Kuick Research provides an in-depth analysis of the Global TNF inhibitors market with special emphasis on the global market size, market trends and dynamics, pricing and cost analysis of products and competitive landscape. Kuick Research analysis is based on extensive research from primary and secondary sources with special emphasis on market opportunities in promising regions globally ensuring an optimistic future forecast of the TNF inhibitors market.

Contents

1. TUMOR NECROSIS FACTOR – AN OVERVIEW

- 1.1 Prologue to Tumor Necrosis Factor
- 1.2 History & Discovery of Tumor Necrosis Factors

2. SIGNIFICANCE OF TUMOR NECROSIS FACTOR

- 2.1 TNF in Cell Signaling & Immunity
 - 2.1.1 Tumor Necrosis Factor Receptor
 - 2.1.2 Tumor Necrosis Factor Receptor
- 2.2 Role of TNF in Cancer
- 2.3 Disease Related to TNF & Members of Its Family

3. WORKING MECHANISM OF TUMOR NECROSIS FACTORS (TNF) INHIBITORS & THEIR THERAPEUTIC EVOLUTION

- 3.1 Tumor Necrosis Factor & Immune Response
- 3.2 Tumor Necrosis Factor Inhibition by Monoclonal Antibodies

4. APPROACHES USED IN DEVELOPMENT OF TNF INHIBITORS

- 4.1 Monoclonal Antibody Approach
- 4.2 Recombinant DNA Technology Approach

5. GLOBAL TUMOR NECROSIS FACTOR ALPHA INHIBITORS PIPELINE OVERVIEW

6. GLOBAL TUMOR NECROSIS FACTOR ALPHA INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 6.1 Unknown
- 6.2 Research
- 6.3 Preclinical
- 6.4 Clinical
- 6.5 Phase-I
- 6.6 Phase-I/II

- 6.7 Phase-II
- 6.8 Phase-II/III
- 6.9 Phase-III
- 6.10 Preregistration
- 6.11 Registered

7. MARKETING GLOBAL TUMOR NECROSIS FACTOR ALPHA INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION

- 7.1 Golimumab (Shinponi, Simponi, Simponi Aria, Simponi I.V, Sympony & Symposony)
- 7.2 Pomalidomide (Imnovid & Pomalyst)
- 7.3 Adalimumab (Humira & Raheara)
- 7.4 Infliximab (Remicade)
- 7.5 Certolizumab Pegol (CIMZIA AutoClicks Prefilled Pen, Cimzia & Simziya)
- 7.6 Apremilast (Otezla)
- 7.7 Infliximab Biosimilar - Celltrion
- 7.8 Lumbricus Rubellus Extract (Inflectra & Remsima)
- 7.9 Adalimumab Biosimilar (AdaliRel & Adfrar)
- 7.10 Infliximab Biosimilar (Infimab)
- 7.11 Infliximab Biosimilar - Bionovis/ The Instituto Vital Brazil
- 7.12 Adalimumab Biosimilar (Exemptia)
- 7.13 Anti-Tumour Necrosis Factor-Alpha Antibody Oral

8. PRICE, DOSAGE & TREATMENT COST ANALYSIS OF COMMERCIALY AVAILABLE TNF BASED THERAPEUTICS

- 8.1 Cimzia (Certolizumab Pegol)
- 8.2 Enbrel (Etanercept)
 - 8.2.1 Benepali – Etanercept Biosimilar
- 8.3 Humira (Adalimumab)
 - 8.3.1 Amjevita – Humira Biosimilar
 - 8.3.2 Cyltezo – Second Biosimilar to Humira
- 8.4 Otezla (Apremilast)
- 8.5 Remicade (Infliximab)
 - 8.5.1 Remsima - Infliximab Biosimilar
 - 8.5.2 Inflectra – Infliximab Biosimilar
- 8.6 Simponi (Golimumab)

9. CURRENT MARKET TRENDS & RECENT ADVANCES IN THE TNF INHIBITORS

SEGMENT

- 9.1 Dominance of TNF Inhibitors in Global Therapeutics Market
- 9.2 Global TNF Inhibitor Market by Indication – Market Size & Growing Opportunity
 - 9.2.1 Rheumatoid Arthritis
 - 9.2.2 Psoriasis and psoriatic arthritis (PsA)
 - 9.2.3 Crohn's Disease
 - 9.2.4 Ankylosing Spondylitis
- 9.3 Global TNF Inhibitors Market by Region
 - 9.3.1 US
 - 9.3.2 Europe
 - 9.3.3 Asia- Pacific
 - 9.3.4 Middle East & Africa (MEA)

10. TNF INHIBITOR- SALES & PATENT ANALYSIS

- 10.1 TNF Inhibitor Market by Sales
 - 10.1.1 Cimzia
 - 10.1.2 Enbrel
 - 10.1.3 Humira
 - 10.1.4 Remicade
- 10.2 TNF Inhibitor Market by Approvals & Patent
- 10.3 TNF Inhibitor Biosimilar Sales Analysis

11. TNF INHIBITORS MARKET DRIVING PARAMETERS

12. RESTRAINING FACTORS OF THE GLOBAL TNF INHIBITORS MARKET

13. GLOBAL – TNF INHIBITORS FUTURE FORECAST & SALES PROJECTIONS

- 13.1 Impact of Biosimilar 'Benepali' on Enbrel Sales
- 13.2 Affordable Alternatives to Humira & Their Effect on Global Humira Sales
- 13.3 Remicade & Its Biosimilar
- 13.4 Conclusion & Executive Summary

14. COMPETITIVE LANDSCAPE

- 14.1 AbbVie
- 14.2 Ablynx
- 14.3 Apogenix
- 14.4 AryoGen Biopharma
- 14.5 Bionovis
- 14.6 CASI Pharmaceuticals
- 14.7 Celltrion
- 14.8 Celgene Corporation
- 14.9 Delenex Therapeutics
- 14.10 Dexa Medica
- 14.11 EPIRUS Biopharmaceuticals
- 14.12 Janssen Biotech
- 14.13 GlaxoSmithKline
- 14.14 HanAll Biopharma
- 14.15 Intas Pharmaceuticals
- 14.16 LEO Pharma
- 14.17 LG Life Sciences
- 14.18 MedImmune
- 14.19 Momenta Pharmaceuticals
- 14.20 Novartis
- 14.21 PROBIOMED
- 14.22 Reliance Life Sciences
- 14.23 Sandoz
- 14.24 Samsung Bioepis
- 14.25 Sanofi-Aventis
- 14.26 Shanghai CP Guojian Pharmaceutical
- 14.27 Shanghai Pharmaceuticals
- 14.28 Simcere Pharmaceutical
- 14.29 Toyama Chemical
- 14.30 Tsumura
- 14.31 UCB
- 14.32 Zydus Cadila

List Of Figures

LIST OF FIGURES

Figure 1-1: Multiple Roles of TNF

Figure 1-2: Historical timeline of Tumor Necrosis Factor

Figure 1-3: Historical Timeline of Tumor Necrosis Factor Inhibitors

Figure 2-1: TNF Factor Types & Their Inhibition

Figure 2-2: Diseases Related to TNF & Its Family Members

Figure 3-1: General Working Mechanism of TNF Inhibitors

Figure 5-1: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024

Figure 5-2: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024

Figure 5-3: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024

Figure 5-4: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024

Figure 8-1: Cimzia - Dose for Crohn's Disease (mg/week)

Figure 8-2: Cimzia - Dose for Rheumatoid Arthritis (US\$)

Figure 8-3: Cimzia - Dose for Psoriatic Arthritis (mg)

Figure 8-4: Cimzia - Dose for Ankylosing Spondylitis (mg)

Figure 8-5: Cimzia (Certolizumab Pegol) – Average Price (US\$)

Figure 8-6: Cimzia - Treatment Cost Analysis, 2018

Figure 8-7: TNF inhibition by Enbrel, Working Mechanism

Figure 8-8: Enbrel - Dosage Forms & Strength (mg & ml)

Figure 8-9: Enbrel - Dosage & Frequency for Arthritis, AS & PsA (mg/Week)

Figure 8-10: Enbrel - Dose for Juvenile Idiopathic Arthritis (mg & mg/kg)

Figure 8-11: Enbrel - Subcutaneous Kit Price (US\$/Unit), 2018

Figure 8-12: Enbrel - Prefilled Syringe Price (US\$/Vial), 2018

Figure 8-13: Global - Enbrel Price by Region (US\$)

Figure 8-14: Enbrel - Treatment Cost Analysis (US\$/Month)

Figure 8-15: Enbrel - Price per QALY Gained (US\$), 2018

Figure 8-16: Humira - Mechanism of Action

Figure 8-17: Humira - Dosage Analysis by Indication (mg)

Figure 8-18: Humira - Dosage Analysis for Crohn's Disease (mg)

Figure 8-19: Humira – Dose for Plaque Psoriasis (mg)

Figure 8-20: Humira - Subcutaneous Kit Price (US\$), 2017

Figure 8-21: Humira - Average Treatment Cost Analysis per Month (US\$), 2017

- Figure 8-22: Otezla - Dose for Plaque Psoriasis
- Figure 8-23: Otezla - Price Analysis (US\$/Unit), 2017
- Figure 8-24: Remicade (Infliximab)- Mode of Action
- Figure 8-25: Remicade - Dose for Crohn's Disease (mg/kg)
- Figure 8-26: Remicade - Dose for Rheumatoid Arthritis (mg/kg)
- Figure 8-27: Remicade- Price Analysis for 100mg Vial (US\$), 2018
- Figure 8-28: Simponi - Availability by Concentration (mg/0.5ml)
- Figure 8-29: Simponi - Dosage Analysis (mg)
- Figure 8-30: Simponi - Price Analysis (US\$/ml), 2018
- Figure 9-1: Global- Therapeutics Market Segmentation by size (%)
- Figure 9-2: Global - Rheumatoid Arthritis Prevalence (per 100,000 Individuals), 2016-2017
- Figure 9-3: Global - Psoriasis & Psoriatic Arthritis Prevalence, 2015-2016
- Figure 9-4: Global- Crohn's Disease Epidemiology (per 100,000 Individuals), 2012-2017
- Figure 9-5: Global - Ankylosing Spondylitis (per 100,000 Individuals), 2018
- Figure 9-6: US - TNF inhibitors Market by Prevalence of Indication (per 1000 Individuals) , 2017
- Figure 9-7: Humira Cost Analysis by Region- US v/s India (US\$/Vial), 2017
- Figure 10-1: Global- Cimzia Sales (US\$ Million), 2016 & 2017
- Figure 10-2: Global - Enbrel Sales (US\$ Million), 2014-2017
- Figure 10-3: Global- Humira Sales (US\$ Million), 2014-2017
- Figure 10-4: Global- Remicade Sales (US\$ Million), 2014-2017
- Figure 10-5: Global - TNF Inhibitors Patent by Number
- Figure 10-6: Patent Analysis - Patent Expiration by Year
- Figure 10-7: Global - TNF Inhibitor Biosimilar Sales (US\$ Million), 2015-2017
- Figure 10-8: Global - Benepali Sales (US\$ Million), 2016-2017
- Figure 11-1: Driving Factors of the TNF Inhibitors Segment
- Figure 12-1: Challenging Factors of the TNF Inhibitors Market
- Figure 13-1: Global – Enbrel Sales Future Forecast (US\$ Million), 2017-2024
- Figure 13-2: Global - Humira Sales Forecast (US\$ Million), 2017-2024
- Figure 13-3: Global - Amjevita Sales Future Forecast (US\$ Million), 2020 & 2024
- Figure 13-4: Global - Remicade Future Sales Forecast (US\$ Million), 2016-2024
- Figure 13-5: Global - Blockbuster TNF Inhibitors Sales (US\$ Billion), 2017
- Figure 14-1: Ablynx - Clinical Pipeline
- Figure 14-2: Apogenix - Clinical Pipeline
- Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
- Figure 14-4: Celgene - Clinical Pipeline
- Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
- Figure 14-6: HanAll Biopharma - Clinical Pipeline

Figure 14-7: Novartis - Clinical Pipeline

Figure 14-8: Sandoz - Clinical Pipeline

Figure 14-9: Toyama Chemical - Clinical Pipeline

Figure 14-10: Zydus Cadila - Clinical Pipeline

I would like to order

Product name: Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

Product link: <https://marketpublishers.com/r/GF9A3D8EE43EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF9A3D8EE43EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

